Nasus Pharma to Participate in Upcoming Investor Conferences
TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences in February and March.
Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Date and time: February 25, 2026, 1:20 p.m. ET
- Location: Virtual ( )
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
BIO Investment & Growth Summit
- Date and time: March 2, 2026, 10:15 a.m. ET
- Location: Miami, FL
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
Citizens Life Sciences Conference
- Date and time: March 11, 2026, 3:25 p.m. ET
- Location: Miami, FL
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
Nasus management will be available for one-on-one meetings during the conferences. Interested parties should contact their conference representative to arrange a meeting.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit or follow on or .
Company Contact
Nasus Pharma Ltd.
Investor Contact
Mike Moyer
LifeSci Advisors
